185 related articles for article (PubMed ID: 23355121)
1. Health state utilities for skeletal-related events secondary to bone metastases.
Matza LS; Chung K; Van Brunt K; Brazier JE; Braun A; Currie B; Palsgrove A; Davies E; Body JJ
Eur J Health Econ; 2014 Jan; 15(1):7-18. PubMed ID: 23355121
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.
Carter JA; Joshi AD; Kaura S; Botteman MF
Pharmacoeconomics; 2012 May; 30(5):373-86. PubMed ID: 22500986
[TBL] [Abstract][Full Text] [Related]
3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.
Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G
Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995
[TBL] [Abstract][Full Text] [Related]
4. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.
Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M
J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250
[TBL] [Abstract][Full Text] [Related]
5. Health state utilities associated with attributes of treatments for hepatitis C.
Matza LS; Sapra SJ; Dillon JF; Kalsekar A; Davies EW; Devine MK; Jordan JB; Landrian AS; Feeny DH
Eur J Health Econ; 2015 Dec; 16(9):1005-18. PubMed ID: 25481796
[TBL] [Abstract][Full Text] [Related]
6. Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases.
Matza LS; Cong Z; Chung K; Stopeck A; Tonkin K; Brown J; Braun A; Van Brunt K; McDaniel K
Patient Prefer Adherence; 2013; 7():855-65. PubMed ID: 24039408
[TBL] [Abstract][Full Text] [Related]
7. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.
Hagiwara M; Delea TE; Chung K
J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707
[TBL] [Abstract][Full Text] [Related]
8. Estimating health state utilities associated with a rare disease: familial chylomicronemia syndrome (FCS).
Matza LS; Phillips GA; Howell TA; Ciffone N; Ahmad Z
J Med Econ; 2020 Sep; 23(9):978-984. PubMed ID: 32479143
[No Abstract] [Full Text] [Related]
9. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.
Botteman M; Barghout V; Stephens J; Hay J; Brandman J; Aapro M
Ann Oncol; 2006 Jul; 17(7):1072-82. PubMed ID: 16670202
[TBL] [Abstract][Full Text] [Related]
11. Canadian health care institution resource utilization resulting from skeletal-related events.
Habib MJ; Merali T; Mills A; Uon V
Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592
[TBL] [Abstract][Full Text] [Related]
12. Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Duran I; Fink MG; Bahl A; Hoefeler H; Mahmood A; Lüftner D; Ghazal H; Wei R; Chung KC; Hechmati G; Green J; Atchison C
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 26865392
[TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Murphy L; McCarthy J; McCrate F; Laing K; Powell E; Seal M; Edwards S
Support Care Cancer; 2013 Jun; 21(6):1557-60. PubMed ID: 23334521
[TBL] [Abstract][Full Text] [Related]
14. Cost of skeletal complications from bone metastases in six European countries.
Pereira J; Body JJ; Gunther O; Sleeboom H; Hechmati G; Maniadakis N; Terpos E; Acklin YP; Finek J; von Moos R
J Med Econ; 2016 Jun; 19(6):611-8. PubMed ID: 26849381
[TBL] [Abstract][Full Text] [Related]
15. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study.
Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A
J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975
[TBL] [Abstract][Full Text] [Related]
16. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
[TBL] [Abstract][Full Text] [Related]
17. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
[No Abstract] [Full Text] [Related]
18. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
Bhowmik D; Hines DM; Intorcia M; Wade RL
J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
[TBL] [Abstract][Full Text] [Related]
19. Short-term disability in solid tumor patients with bone metastases and skeletal-related events.
Qian Y; Song X; Zhang K; Balakumaran A; Arellano J
J Med Econ; 2015 Mar; 18(3):210-8. PubMed ID: 25426582
[TBL] [Abstract][Full Text] [Related]
20. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.
Jensen AØ; Jacobsen JB; Nørgaard M; Yong M; Fryzek JP; Sørensen HT
BMC Cancer; 2011 Jan; 11():29. PubMed ID: 21261987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
